Oteseconazole CAS# 1340593-59-0 奥特康唑

Oteseconazole (VT-1161) is a potent, selective oral antifungal agent that inhibits fungal CYP51 (lanosterol 14α-demethylase), disrupting ergosterol synthesis. In preclinical assays, it showed strong activity against Candida spp. (MIC90 0.002–0.06 µg/mL) and Aspergillus spp. (MIC90 0.03–0.12 µg/mL), including azole-resistant strains. Oteseconazole displayed >2000-fold selectivity for fungal CYP51 over human CYP enzymes, minimizing off-target effects. In murine models of disseminated and vulvovaginal candidiasis, it significantly reduced fungal burden and improved survival at low oral doses. Pharmacokinetic studies demonstrated high oral bioavailability, long half-life, and extensive tissue distribution, supporting its development for recurrent vulvovaginal candidiasis and systemic fungal infections.